{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:09:28Z","timestamp":1781896168414,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015760","name":"Inserm Transfert","doi-asserted-by":"publisher","award":["UAR 3556"],"award-info":[{"award-number":["UAR 3556"]}],"id":[{"id":"10.13039\/501100015760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-PEBI-0009"],"award-info":[{"award-number":["ANR-22-PEBI-0009"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-24-INBS-0005 FBI BIOGEN"],"award-info":[{"award-number":["ANR-24-INBS-0005 FBI BIOGEN"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004794","name":"National Centre for Scientific Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015510","name":"Infrastructures en Biologie Sant\u00e9 et Agronomie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015510","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001677","name":"INSERM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009371","name":"Universit\u00e9 de Nantes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031212","name":"Network of European Institutes for Advanced Study","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013414","name":"Regional Council of Pays de la Loire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013414","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201095","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:25:49Z","timestamp":1763659549000},"page":"201095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers"],"prefix":"10.1016","volume":"33","author":[{"given":"Tina","family":"Briolay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacien","family":"Petithomme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermelyne","family":"Gravoueille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fresquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Lambot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Cossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Mouratou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Fortun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Bernardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Qu\u00e9m\u00e9ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Maillasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Boisgerault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Davodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Pecorari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-3747","authenticated-orcid":false,"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201095_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody-drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2025.201095_bib2","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.3390\/molecules25204764","article-title":"Antibody-Drug Conjugates for Cancer Therapy","volume":"25","author":"Hafeez","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.omton.2025.201095_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.tibtech.2015.03.012","article-title":"Non-immunoglobulin scaffolds: a focus on their targets","volume":"33","author":"\u0160krlec","year":"2015","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.omton.2025.201095_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s13238-017-0386-6","article-title":"In vitro-engineered non-antibody protein therapeutics","volume":"9","author":"Simeon","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.omton.2025.201095_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/srep37274","article-title":"The archaeal \u201c7 kDa DNA-binding\u201d proteins: extended characterization of an old gifted family","volume":"6","author":"Kalichuk","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omton.2025.201095_bib6","doi-asserted-by":"crossref","first-page":"17983","DOI":"10.1073\/pnas.0702963104","article-title":"Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD","volume":"104","author":"Mouratou","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2025.201095_bib7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/protein\/gzs106","article-title":"Tolerance of the archaeal Sac7d scaffold protein to alternative library designs: characterization of anti-immunoglobulin G Affitins","volume":"26","author":"B\u00e9har","year":"2013","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.omton.2025.201095_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097438","article-title":"Potent and Specific Inhibition of Glycosidases by Small Artificial Binding Proteins (Affitins)","volume":"9","author":"Correa","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201095_bib9","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1002\/bit.26989","article-title":"Whole-bacterium ribosome display selection for isolation of highly specific anti-Staphyloccocus aureus Affitins for detection- and capture-based biomedical applications","volume":"116","author":"B\u00e9har","year":"2019","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omton.2025.201095_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/bit.26463","article-title":"A novel, smaller scaffold for Affitins: Showcase with binders specific for EpCAM","volume":"115","author":"Kalichuk","year":"2018","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.omton.2025.201095_bib11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.chroma.2016.02.068","article-title":"Affitins as robust tailored reagents for affinity chromatography purification of antibodies and non-immunoglobulin proteins","volume":"1441","author":"B\u00e9har","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.omton.2025.201095_bib12","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1021\/acs.bioconjchem.7b00374","article-title":"Nanofitin as a New Molecular-Imaging Agent for the Diagnosis of Epidermal Growth Factor Receptor Over-Expressing Tumors","volume":"28","author":"Goux","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.omton.2025.201095_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nucmedbio.2017.04.006","article-title":"Regiospecific radiolabelling of Nanofitin on Ni magnetic beads with [18F]FBEM and in vivo PET studies","volume":"51","author":"Dammicco","year":"2017","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.omton.2025.201095_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.201095_bib15","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201095_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.omton.2025.201095_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/mco.2022.2522","article-title":"Novel approaches for the treatment of unresectable malignant pleural mesothelioma: A focus on immunotherapy and target therapy (Review)","volume":"16","author":"Rijavec","year":"2022","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201095_bib18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1200\/JCO.21.01567","article-title":"New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options","volume":"40","author":"Tsao","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201095_bib19","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/cncr.33433","article-title":"Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies","volume":"127","author":"Hu","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.omton.2025.201095_bib20","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.201095_bib21","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1158\/1078-0432.CCR-14-0804","article-title":"Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma","volume":"20","author":"Hassan","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omton.2025.201095_bib22","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Hassan","year":"2007","journal-title":"Cancer Immun."},{"key":"10.1016\/j.omton.2025.201095_bib23","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1166\/jbn.2015.2063","article-title":"Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications","volume":"11","author":"Prantner","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.omton.2025.201095_bib51","doi-asserted-by":"crossref","first-page":"33123","DOI":"10.1074\/jbc.M112.381756","article-title":"Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights","volume":"287","author":"Ma","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.omton.2025.201095_bib24","first-page":"274","article-title":"Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells","volume":"28","author":"Vallera","year":"2013","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.omton.2025.201095_bib25","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2025.201095_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2011.09.063","article-title":"Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress","volume":"161","author":"Lammers","year":"2012","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.omton.2025.201095_bib27","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/238431","article-title":"Functional Alteration of Natural Killer Cells and Cytotoxic T Lymphocytes upon Asbestos Exposure and in Malignant Mesothelioma Patients","volume":"2015","author":"Nishimura","year":"2015","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.omton.2025.201095_bib28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/bjc.2017.269","article-title":"Evaluating the effect of immune cells on the outcome of patients with mesothelioma","volume":"117","author":"Chee","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.201095_bib29","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/ijc.32363","article-title":"NK- and T-cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA-4 therapy","volume":"145","author":"Sottile","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.omton.2025.201095_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.660039","article-title":"Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma","volume":"11","author":"Hiltbrunner","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.omton.2025.201095_bib31","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.18632\/oncotarget.2093","article-title":"A Fc\u03b3RIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy","volume":"5","author":"Turini","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.201095_bib32","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fc\u03b3 receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201095_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41416-018-0341-1","article-title":"High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy","volume":"120","author":"Rataj","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2025.201095_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40364-019-0169-8","article-title":"Mesothelin as a biomarker for targeted therapy","volume":"7","author":"Lv","year":"2019","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2025.201095_bib35","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jmb.2008.09.016","article-title":"Artificial Binding Proteins (Affitins) as Probes for Conformational Changes in Secretin PulD","volume":"383","author":"Krehenbrink","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.omton.2025.201095_bib36","doi-asserted-by":"crossref","first-page":"21391","DOI":"10.1021\/acsami.9b05702","article-title":"Multivalent Affidendrons with High Affinity and Specificity toward Staphylococcus aureus as Versatile Tools for Modulating Multicellular Behaviors","volume":"11","author":"Vukojicic","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.omton.2025.201095_bib37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.drudis.2015.09.004","article-title":"Challenges and opportunities for non-antibody scaffold drugs","volume":"20","author":"Vazquez-Lombardi","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.omton.2025.201095_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1200652","article-title":"Rapid nanobody-based imaging of mesothelin expressing malignancies compatible with blocking therapeutic antibodies","volume":"14","author":"Benloucif","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201095_bib39","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/pro.3148","article-title":"Monobodies and other synthetic binding proteins for expanding protein science","volume":"26","author":"Sha","year":"2017","journal-title":"Protein Sci."},{"key":"10.1016\/j.omton.2025.201095_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142304","article-title":"Use of the Nanofitin Alternative Scaffold as a GFP-Ready Fusion Tag","volume":"10","author":"Huet","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.omton.2025.201095_bib41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1177\/1087057114557781","article-title":"High-Throughput Screening of Formulations to Optimize the Thermal Stability of a Therapeutic Monoclonal Antibody","volume":"20","author":"Niedziela-Majka","year":"2015","journal-title":"SLAS Discovery"},{"key":"10.1016\/j.omton.2025.201095_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.nbt.2018.04.006","article-title":"Quality and cost assessment of a recombinant antibody fragment produced from mammalian, yeast and prokaryotic host cells: A case study prior to pharmaceutical development","volume":"44","author":"Lebozec","year":"2018","journal-title":"N. Biotech."},{"key":"10.1016\/j.omton.2025.201095_bib43","doi-asserted-by":"crossref","first-page":"27264","DOI":"10.1039\/C9RA03668G","article-title":"Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and in vivo biodistribution improvements","volume":"9","author":"Resnier","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.omton.2025.201095_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ymeth.2018.09.010","article-title":"Bispecific applications of non-immunoglobulin scaffold binders","volume":"154","author":"Hober","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.omton.2025.201095_bib45","doi-asserted-by":"crossref","first-page":"636","DOI":"10.3390\/biom13040636","article-title":"Engineering of a Bispecific Nanofitin with Immune Checkpoint Inhibitory Activity Conditioned by the Cross-Arm Binding to EGFR and PDL1","volume":"13","author":"Jacquot","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.omton.2025.201095_bib46","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.3389\/fimmu.2019.01593","article-title":"A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer","volume":"10","author":"Del Bano","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201095_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1060905","article-title":"A tri-specific killer engager against mesothelin targets NK cells towards lung cancer","volume":"14","author":"Kennedy","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2025.201095_bib48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2147\/IJN.S435787","article-title":"Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies","volume":"19","author":"Briolay","year":"2024","journal-title":"IJN"},{"key":"10.1016\/j.omton.2025.201095_bib49","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.00160210","article-title":"Recognition of pleural mesothelioma by mucin-1(950-958)\/human leukocyte antigen A\u22170201-specific CD8+ T-cells","volume":"38","author":"Roulois","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.omton.2025.201095_bib50","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","article-title":"Single-Cell View of Tumor Microenvironment Gradients in Pleural Mesothelioma","volume":"14","author":"Giotti","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.201095_bib52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/978-1-61779-379-0_18","article-title":"Ribosome display for the selection of Sac7d scaffolds","volume":"805","author":"Mouratou","year":"2012","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omton.2025.201095_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/protein\/gzm064","article-title":"Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells","volume":"21","author":"Behar","year":"2008","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.omton.2025.201095_bib54","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/bioinformatics\/btz921","article-title":"Logomaker: beautiful sequence logos in Python","volume":"36","author":"Tareen","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.omton.2025.201095_bib55","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ajpath.2010.12.014","article-title":"Identification of novel markers for the diagnosis of malignant pleural mesothelioma","volume":"178","author":"Gueugnon","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.omton.2025.201095_bib56","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/482089","article-title":"In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer","volume":"2015","author":"Cl\u00e9menceau","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.omton.2025.201095_bib57","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992500164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S295032992500164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:59Z","timestamp":1778938679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S295032992500164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S295032992500164X"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201095","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201095"}}